Home / Oligonucleotides and Peptides / Discovery / Peptide / Peptide-Based Conjugates

Peptide-Based Conjugates

Specialized conjugate synthesis transforming complex peptide designs into targeted therapies with precision, pace, and reliability.

Addressing the Complexity of Peptide Conjugates

Peptide-based conjugates improve targeting, stability, and exposure, but they also introduce added complexity across synthesis, conjugation chemistry, impurity control, and CMC strategy. Successful development depends on early alignment between peptide design, conjugation approach, analytics, and manufacturability.

WuXi TIDES supports peptide-based conjugates through an integrated CRDMO platform that brings peptide synthesis, conjugation process development, analytical characterization, and GMP manufacturing together. By developing these elements in parallel, conjugation strategy, linker and payload selection, and scalability considerations are addressed early, reducing downstream risk as programs move toward IND and clinical development.

Peptide CMC Development

Broad Experience across Peptide Conjugates

WuXi TIDES supports a range of peptide conjugates, including peptide–small molecule conjugates, peptide–lipid conjugates, and other ligand- or payload-modified peptides. Flexible process design and early CMC insight enable programs to advance efficiently as complexity and material demand increase.

With extensive solid-phase peptide synthesis capacity and proven execution at scale, programs can transition smoothly from preclinical studies to clinical and commercial manufacturing.

Scalable by Design

Peptide conjugates developed on manufacturing-ready platforms backed by >100,000 L SPPS capacity

Early CMC Insight

Conjugation strategy, impurity control, and manufacturability addressed early to avoid late-stage surprises

Integrated Peptide + Conjugation CRDMO

Single-platform development covering peptide synthesis, conjugation chemistry, analytical, and GMP manufacturing

Advanced Modifications Expertise

We support both N-terminal and C-terminal modifications as well as internal modifications where needed.

Our experience spans cleavable and non-cleavable linkers, allowing you to fine-tune conjugate performance for optimal stability, activity or targeting.

Whether you are developing peptide–drug conjugates or fluorescent-labeled peptides, we deliver precisely engineered molecules to meet your research and development goals.

Learn More

Our quality

Quality is central to every peptide conjugate we deliver, backed by a strong track record in excellence. From payload selection to final construct, we apply rigorous analytical controls to ensure accuracy, purity, and consistency.

Our experienced teams approach each complex conjugate with precision and care, turning complexity into confidence and delivering reliable, high-quality outcomes that drive smooth downstream development and successful advancement of targeted peptide therapeutics.

Our locations

Our global network supports peptide conjugate synthesis with scale, specialization, and regional flexibility. With key facilities across China, Singapore, the U.S., and Switzerland, we offer integrated peptide and conjugation capabilities close to your development hubs.

Each site operates with the same precision and responsiveness – ensuring your complex molecules progress without delay. By combining local access with global coordination, we help you move from idea to breakthrough with confidence and purpose-driven pace.

Learn more

Our history

From its foundation, our journey has been defined by a commitment to innovation, quality, and strong partnerships, driven by a purpose-driven pace.

We’ve evolved into a leading CRDMO with a perfectly orchestrated platform, consistently expanding our global footprint and capabilities to accelerate breakthroughs for our partners and patients worldwide.

Learn more